2,4-pyrimidinediamine compounds and their uses
US-2015158823-A1 · Jun 11, 2015 · US
Besylate salt of a BTK inhibitor
US9604936B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9604936-B2 |
| Application number | US-201314058847-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 21, 2013 |
| Priority date | Aug 10, 2010 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a salt form, and compositions thereof, useful as an inhibitor of one or more protein kinases and which exhibits desirable characteristics for the same.
First claim
Opening claim text (preview).
We claim: 1. Compound 2: 2. The compound according to claim 1 , wherein said compound is in solid form. 3. The compound according to claim 2 , wherein said compound is crystalline. 4. The compound according to claim 3 , wherein said compound is a crystalline solid substantially free of amorphous Compound 2. 5. The compound according to claim 1 , wherein said compound is substantially free of impurities. 6. A composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier or excipient. 7. The compound according to claim 2 , wherein the solid form of the compound is characterized by at least one peak selected from the Form P1PXRD spectra depicted in FIG. 2 . 8. The compound according to claim 7 , wherein the solid form of the compound is characterized by at least two peaks selected from the Form P1PXRD spectra depicted in FIG. 2 . 9. The compound according to claim 8 , wherein the solid form of the compound is characterized by at least three peaks selected from the Form P1PXRD spectra depicted in FIG. 2 . 10. The compound according to claim 9 , wherein the solid form of the compound is characterized by at least four peaks selected from the Form P1PXRD spectra depicted in FIG. 2 . 11. The compound according to claim 2 , wherein the solid form of the compound is characterized by at least one peak selected from the Form P22PXRD spectra depicted in FIG. 6 . 12. The compound according to claim 11 , wherein the solid form of the compound is characterized by at least two peaks selected from the Form P22PXRD spectra depicted in FIG. 6 . 13. The compound according to claim 12 , wherein the solid form of the compound is characterized by at least three peaks selected from the Form P22PXRD spectra depicted in FIG. 6 . 14. The compound according to claim 13 , wherein the solid form of the compound is characterized by at least four peaks selected from the Form P22PXRD spectra depicted in FIG. 6 .
Assignees
Inventors
Classifications
Drugs for immunological or allergic disorders · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
specific for metastasis · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9604936B2 cover?
- The present invention provides a salt form, and compositions thereof, useful as an inhibitor of one or more protein kinases and which exhibits desirable characteristics for the same.
- Who is the assignee on this patent?
- Celgene Avilomics Res Inc, Celgene Car Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D239/48. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).